Pateclizumab reduced the DAS28 ( 4 ) - ESR response ( -1.89 ) at 12 weeks , however , this did not reach statistical significance compared to placebo ( -1.54 ) , while adalimumab ( -2.52 ) differed significantly from both placebo and pateclizumab .